Therapeutic implications of interleukin-10 in inflammatory bowel disease.
Enhanced production of proinflammatory cytokines has been described in inflammatory bowel disease. The effect of interleukin (IL)-10, a cytokine with antiinflammatory activity, or anti-IL-10, on cytokine production by cultured colonic mucosa or blood mononuclear cells from patients with active inflammatory bowel disease was evaluated. Addition of IL-10 to the culture medium of colonic tissues or blood mononuclear cells resulted in inhibition of both IL-1 beta and tumor necrosis factor-alpha production and augmentation of IL-1 receptor antagonist production. Conversely, neutralization of endogenous IL-10 was found to augment both tumor necrosis factor-alpha and IL-1 beta production and inhibit IL-1 receptor antagonist production. In addition, the production of IL-10 by mononuclear cells was suppressed by prednisolone. In conclusion, IL-10 and related molecules may be useful in the treatment of inflammatory bowel disease.
Shirachi
A
A
Second Department of Medicine, Kurume University School of Medicine, Japan.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D016753:Interleukin-10 / Q000627:therapeutic use*; D009924:Organ Culture Techniques; D011994:Recombinant Proteins / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D011994:Recombinant Proteins; D016753:Interleukin-10